Decentralized Clinical Trials for Rare Disease Patients

This guide discusses the implementation of decentralized clinical trials (DCTs) specifically tailored for rare disease patients. It outlines the challenges faced by these patients and their families, emphasizing the importance of understanding their journey to improve trial protocols. The document details how DCTs can enhance patient recruitment and retention by allowing participation from home or community settings, especially during the COVID-19 pandemic. It highlights the role of Home Trial Support (HTS) services in providing tailored care, reducing travel burdens, and ensuring patient comfort. The guide stresses the need for trial protocols to be designed with the patient's needs in mind, advocating for proactive conversations among study sponsors, sites, and vendors. Additionally, it addresses the significance of setting clear expectations for patients and families regarding trial participation, including the potential disruptions and the importance of flexibility in trial schedules. Overall, the document aims to provide insights into creating a patient-centered approach in decentralized clinical trials.